Table 1 Baseline patient characteristics

Slides:

Advertisements

Similar presentations

Fig. 4-1, p Fig. 4-2, p. 109 Fig. 4-3, p. 110.

Advertisements

P.464. Table 13-1, p.465 Fig. 13-1, p.466 Fig. 13-2, p.467.

Fig. 11-1, p p. 360 Fig. 11-2, p. 361 Fig. 11-3, p. 361.

Table 6-1, p Fig. 6-1, p. 162 p. 163 Fig. 6-2, p. 164.

Fig.1 Complexity of the surgeries according to BAS. Histogram.

Volume 144, Issue 1, Pages (January 2017)

Table 1 Cause of death for arrested organ donors

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

Table 1 Patient characteristics

Fig. 1 Diagram of method C for bronchial closure

Fig. 1 Clinical model of coronary collateral flow

Table 1 Staging of resected tumours of the oesophagus

Fig. 4 The blood path conversion to VAD by relocating the tubing clamps. Stasis in the oxygenator is avoided by recirculating its volume, thus allowing.

Table 1 Baseline characteristics of mitral valve operated patientsaaAF, atrial fibrillation; LA, left atrium; LVEDD, left ventricular end-diastolic.

Table 2 Laboratory and echocardiographic values before LVAD implantation in the two groups. From: Reversibility of fixed pulmonary hypertension in left.

Table 1 Comparison of perioperative patient characteristics by groups

Fig. 1 Log-rank test comparing survival in patients undergoing surgical repair with those treated with TEVAR. Black line: TEVAR; grey line: surgical repair.

Volume 64, Pages e1-e3 (January 2017)

Prognosis of younger patients in non-small cell lung cancer

Table 1 Hospital mortality

From: Long-term respiratory functional results after pneumonectomy

Fig. 1 Protocol for oral sildenafil administration for persistent postoperative pulmonary hypertension in paediatric patients. Each dose was given via.

Table 1 Recipient’s characteristics.

Fig. 3 Summary estimates of the relative risks for the different surgical techniques for late mortality. Comparing the two main techniques, EVR showed.

Table 1 The 5 stages of constructing a BET

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Intervista a Lucio Crinò

Volume 119, Issue 4, Pages (October 2000)

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Survival After Surgical Resection for Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease Anders Bugge, MD, May Brit Lund, MD, PhD, Cathrine.

Primary non-Hodgkin’s lymphoma of the lung

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Surgical Management of Advanced Non-Small Cell Lung Cancer Is Decreasing But Is Associated With Improved Survival Elizabeth A. David, MD, Robert J. Canter,

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Cytologically malignant margins of wedge resected stage I non-small cell lung cancer Noriyoshi Sawabata, MD, Akihide Matsumura, MD, Mitsunori Ohota, MD,

Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro.

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

Case 1: Introduction. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Volume 119, Issue 4, Pages (October 2000)

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Clinical marker confirmation using centrally assessed progression-free survival data in patients with advanced non-small cell lung cancer with non-squamous.

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Overall survival in the IFCT trial comparing a single agent therapy arm (vinorelbine or gemcitabine) and the doublet carboplatin plus weekly paclitaxel.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

Conditional Survival After Surgical Intervention in Patients With Non-Small Cell Lung Cancer Takayuki Fukui, MD, Toshiki Okasaka, MD, Koji Kawaguchi,

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer. A meta-analysis of two randomized trials E Mitry, A Fields,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Impact of positive pleural lavage cytology on survival in patients having lung resection for non–small-cell lung cancer: An international individual patient.

Differences in Patterns of Recurrence in Early-Stage Versus Locally Advanced Non- Small Cell Lung Cancer Feiran Lou, MD, MS, Camelia S. Sima, MD, MS,

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Selective Mediastinal Lymphadenectomy for Clinico-Surgical Stage I Non–Small Cell Lung Cancer Morihito Okada, MD, PhD, Toshihiko Sakamoto, MD, PhD, Tsuyoshi.

Douglas E. Paull, MD, Glenda M. Updyke, PA-C, Michael A

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Neal S Goldstein, MD The Annals of Thoracic Surgery

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer D. Zylla, M.A. Kuskowski, K. Gupta, P. Gupta

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Treatment of Stage III Non-small Cell Lung Cancer

Kaplan–Meier curve for progression-free survival for gefitinib versus doublet chemotherapy in three phase III trials in first-line nonsmall cell lung cancer.

A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Presentation transcript:

Table 1 Baseline patient characteristics From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Table 2 Cycles of chemotherapy received by baseline WHO performance status and by chosen chemotherapy regimen From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Table 3 Surgery From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Fig. 4 Survival by tumour stage. From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Fig. 3 Forest plots. From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Fig. 1 Overall survival. From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Table 4 Site(s) of first relapse From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.

Fig. 2 Progression-free survival. From: Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg. 2004;26(1):173-182. doi:10.1016/j.ejcts.2004.03.041 Eur J Cardiothorac Surg | Elsevier B.V.